TX-MAVENIR
21.4.2021 15:02:15 CEST | Business Wire | Press release
Koch Strategic Platforms (“KSP”), a subsidiary of Koch Investments Group, announced today it has signed an agreement for a strategic minority equity investment in Mavenir (the “Company”). Affiliates of Siris Capital Group, LLC (“Siris”), a leading technology focused private equity firm, will remain majority equity holders.
Mavenir is the only U.S. based provider of end-to-end, cloud-native software to meet the growing demand for 5G digital transformation by communication service providers (“CSPs”) and enterprises.
KSP, which focuses on growth equity through four thematic sectors—computing and connectivity, industrial automation, energy transformation, and health care—is a natural partner for Mavenir’s 5G transformational efforts. KSP aims to be a partner beyond capital investment by leveraging the resources and capabilities of Koch Industries to accelerate growth for companies in which it invests, as well as identifying new platforms for Koch.
“We have built a next-generation software platform that has driven, and will continue to drive, the digital transformation of mission-critical networks. Together with KSP and our service provider customers, we expect to bring innovation and 5G to revolutionize industries such as energy, industrial automation, and health care,” said Pardeep Kohli, President and Chief Executive Officer of Mavenir. “Not only do we have the only end-to-end, cloud-native, 5G software platform in the world, but we also have strong and extensive relationships with CSPs and proven deployments of our technology around the globe. With 5G here, Mavenir is well positioned to build the future of networks.”
“We are extremely proud of what Mavenir has achieved to date and excited about partnering with KSP to drive continued innovation,” said Hubert de Pesquidoux, Siris Executive Partner and Executive Chairman of Mavenir. “The combination of Mavenir’s 5G software platform and Koch Industries’ presence in relevant industry verticals will accelerate the Company’s participation in the massive digital transformation opportunity.”
David Park, President of KSP, said, “We’re taking material minority equity positions in innovative, disruptive companies with strong management teams that operate in industries with significant tailwinds. We want to partner with companies that can transform Koch Industries for the future. Mavenir checks all the boxes.”
Frank Baker, Co-Founder of Siris, said, “We have been anticipating the transformation of mobile networks, and that time has arrived. Mavenir is uniquely positioned to lead the 5G transformation given its investment in disruptive products, like OpenRAN, and extensive relationship with over 250 CSPs. We are excited about the partnership with KSP and the strategic growth opportunities that we will tackle together.”
Michael Hulslander, Managing Director at Siris, added, “By strengthening Mavenir’s balance sheet, this investment allows the Company to accelerate innovation in CSP and enterprise networks. We look forward to partnering with KSP to enhance Mavenir’s already exciting trajectory.”
Goldman Sachs & Co. LLC and Guggenheim Securities, LLC acted as financial advisors to Mavenir. Sidley Austin LLP provided legal counsel to Mavenir and Jones Day LLP provided legal counsel to KSP.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, visit www.mavenir.com
About Koch Strategic Platforms:
With offices in Atlanta and Wichita, KSP desires to be the preferred investment partner of growth focused, strategic companies who are innovating in "new economy" industries. Created in 2020, the KSP team pursues public and private investments with companies where long-term mutual benefit can be realized.
About Koch Industries, Inc.:
Based in Wichita, Kansas, Koch Industries, Inc. is one of the largest private companies in America, with estimated annual revenues as high as $115 billion, according to Forbes. It owns a diverse group of companies involved in refining, chemicals, and biofuels; forest and consumer products; fertilizers; polymers and fibers; process and pollution control systems; electronics, software and data analytics; minerals; glass; automotive components; ranching; commodity trading; and investments. Since 2003, Koch companies have invested nearly $133 billion in growth and improvements. For more news and information, visit www.KOCHind.com .
About Siris:
Siris is a leading private equity firm that invests primarily in technology companies with mission-critical products and services. Siris’ development of proprietary research to identify opportunities and its extensive collaboration with its Executive Partners are integral to its approach. Siris’ Executive Partners are experienced senior operating executives that actively participate in key aspects of the transaction lifecycle to help identify opportunities and drive strategic and operational value. Siris is based in New York and Silicon Valley and has raised nearly $6 billion in cumulative capital commitments. For more information, visit www.siris.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005355/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
